Novartis AG is expected to post a 34 per cent jump in third-quarter net profit to $2.11 billion, a Reuters poll showed, as it benefits from comparisons with a tough year-ago quarter.

Novartis was hit in the third quarter of 2007 by generic competition to products like blood pressure tablet Lotrel and herpes treatment Famvir, as well as the withdrawal of bowel drug Zelnorm in the United States.

"Overall we expect a another solid set of results that show recovery in Pharma is on track supported by good growth in Consumer Health and Sandoz (generics) divisions," Citi analyst Amit Roy said.

Following is a breakdown of analysts' forecasts for Novartis. The company is due to report figures on Oct 20.